• Multianimal MRI for Pancreatic Tumor Monitoring

  2026-08-15

  Kempinska and colleagues describe a four-chamber MRI workflow that enables high-resolution imaging of up to four pancreatic cancer-bearing mice in one acquisition session. Applied to the clinically relevant KPC model, the protocol supports tumor detection, longitudinal measurement, trial enrollment, and proof-of-concept assessment of gemcitabine while reducing imaging time and resource demands.

• Renal Blood Flow, Norepinephrine, and Sepsis

  2026-08-14

  This study examined how potassium-channel blockade changes renal vascular responses to norepinephrine and phenylephrine in septic rats. Its central finding is that blocking Kir6.1 or KCa1.1 channels may not alter basal renal blood flow, yet can markedly worsen pressor-associated renal hypoperfusion, revealing a context-dependent protective role for vascular potassium channels during sepsis.

• XYD113: A Selective GSPT1 Degrader for MYC-Driven Cancer

  2026-08-14

  The reference study presents XYD113 as a potent molecular glue degrader that selectively eliminates GSPT1 through a CRBN-dependent ubiquitin–proteasome mechanism. Its activity across MYC-overexpressing cancer models, favorable selectivity profile, and preliminary oral xenograft efficacy support further investigation while leaving important clinical and mechanistic questions unresolved.

• Fucoidan: Designing Mechanism-Resolved Cancer Assays

  2026-08-13

  Fucoidan is a Sulfated α-L-Fucan with anticancer activity that should be evaluated through layered, mechanism-resolved assays rather than viability alone. This guide connects caveolin-1, apoptosis, migration, and immune context to practical breast cancer research decisions.

• CHK1 Inhibition in Breast Cancer: ER/PR-Dependent Effects

  2026-08-13

  The reference study shows that CHK1 inhibition is not uniformly useful across breast cancer subtypes: it enhances adriamycin sensitivity in ER-/PR-/HER2- disease but has limited chemosensitizing value in ER+/PR+/HER2- cells. Its most important contribution is a receptor-context framework linking CHK1 inhibition to distinct cell-cycle, transcriptional, and apoptotic mechanisms.

• Gemcitabine HCl in MRI-Guided Tumor Studies

  2026-08-12

  Gemcitabine HCl combines a mechanistically direct cytotoxic readout with longitudinal, quantitative tumor imaging in pancreatic cancer models. This workflow shows how to connect in vitro cytotoxicity testing, treatment scheduling, and multianimal MRI for more efficient preclinical study design.

• Bufuralol (hydrochloride): Reliable Assay Workflows

  2026-08-12

  Learn how Bufuralol (hydrochloride), SKU C5043, can be integrated into controlled cell viability, organoid, and β-adrenergic modulation studies. This scenario-based guide covers interpretation, solvent compatibility, preparation, data comparison, and practical vendor selection.

• Human iPSC Intestinal Organoids for Pharmacokinetics

  2026-08-11

  A 2025 study established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids can be cryopreserved, maintained over extended culture, and converted into intestinal epithelial monolayers with enterocyte-associated CYP and transporter activities, creating a more human-relevant platform for pharmacokinetic research.

• Budesonide Workflow for Airway Inflammation Research

  2026-08-11

  Build more informative asthma inflammation models by pairing Budesonide’s anti-inflammatory activity with biomimetic pulmonary permeability assays. This workflow separates cellular efficacy from membrane partitioning, helping researchers optimize exposure, interpret assay discordance, and improve respiratory disease research.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus

  2026-08-10

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus is designed for generating randomly Cy3-modified RNA probes by T7 in vitro transcription. It supports research workflows such as in situ hybridization, Northern blot hybridization, and fluorescence-based RNA detection, but it is not intended for diagnostic, clinical, or therapeutic use.

• IDH1-R132H Autopalmitoylation and Cancer Metabolism

  2026-08-09

  A recent Nature Chemical Biology study identifies C269 autopalmitoylation as a mutation-specific regulator of IDH1-R132H. By integrating chemoproteomics, biochemical analysis, and cancer-cell experiments, the authors connect fatty-acid availability with mutant IDH1 activity, 2-HG-associated epigenetic changes, and cellular transformation.

• MK-571 (L-660,711): Reliable Cell Assays

  2026-08-08

  This scenario-based guide explains how MK-571 (L-660,711), SKU B7023, can help researchers separate leukotriene receptor biology from ABCC1/MRP1-mediated effects in viability, proliferation, and cytotoxicity assays. It covers controls, DMSO handling, interpretation, and practical supplier-selection criteria for reproducible laboratory workflows.

• Bufuralol Hydrochloride: An Assay-to-PK Framework

  2026-08-07

  Bufuralol hydrochloride is a non-selective β-adrenergic receptor antagonist suited to mechanistic cardiovascular pharmacology research. This article presents an assay-to-pharmacokinetic framework that connects its partial agonist behavior with human iPSC-derived intestinal organoid models while clearly separating established evidence from research hypotheses.

• Gemcitabine HCl in Pancreatic Cancer: Assay Rigor and Imagin

  2026-08-07

  Explore how Gemcitabine HCl advances preclinical pancreatic cancer research through rigorous cytotoxicity assay design and integration with multianimal MRI imaging. This article offers in-depth, practical guidance for maximizing translational impact using Gemcitabine HCl.

• Metabolomics Signatures of Carbapenemase-Producing Enterobac

  2026-08-06

  This study applies LC-MS/MS metabolomics to identify specific metabolic biomarkers distinguishing carbapenemase-producing Enterobacterales (CPE) from non-resistant strains. The rapid, machine learning–driven approach offers mechanistic insight into resistance phenotypes and holds promise for developing faster diagnostic tools.

553 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page